doi:10.1111/1755-5922.12064
Studied for effects on metabolism, energy regulation, and fat cell activity
Convenience: Skip the waiting room, save travel time, and fit wellness into your schedule
Trends Endocrinol
14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 adult patients with type 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100 units/mL, with or without metformin, to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or placebo
It is not approved by the FDA for fat loss or any other use, and any clinical application falls under the supervision of a licensed medical provider